Dyne Therapeutics, Inc. (DYN) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.72: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Elevated put/call ratio: 11.50; Below-average business quality.
Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases, with lead assets z-rostudirsen (DYNE-251) for DMD exon 51 skipping and z-basivarsen (DYNE-101) for DM1. BLA submission for z-rostudirsen planned Q2 2026 for... Read more
Sell if holding. Engine safety override at $18.72: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Elevated put/call ratio: 11.50; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Score 5.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Dyne Therapeutics, Inc.
About Dyne Therapeutics, Inc.
Dyne Therapeutics' lead DMD program, z-rostudirsen, met its primary endpoint in the DELIVER registrational expansion cohort in December 2025, demonstrating a statistically significant mean muscle content-adjusted dystrophin expression of 5.46% of normal at six months (p<0.0001). A BLA submission to the FDA under Accelerated Approval is planned for Q2 2026, with a potential U.S. commercial launch targeted for Q1 2027. The company has no approved products and reported net losses of $446.2 million in 2025 and $317.4 million in 2024, with $1.1 billion in cash, cash equivalents, and marketable securities at December 31, 2025.
Dyne generates no product revenue; operations are financed through equity raises and debt. In June 2025, the company entered a Loan Agreement with Hercules providing term loans of up to $275.0 million across multiple tranches — $100.0 million drawn at signing and $50.0 million drawn under the December 2025 First Amendment — with remaining tranches available subject to specified clinical, regulatory, and commercial milestones. Management estimates the $1.1 billion cash position will fund operations into Q1 2028. The second lead program, z-basivarsen for myotonic dystrophy type 1, is in the Phase 1/2 ACHIEVE trial; BLA submission is planned for early Q3 2027 with a potential launch targeted for Q1 2028. Four additional DMD exon-skipping candidates (DYNE-253, DYNE-245, DYNE-244, and DYNE-255) are in IND-enabling studies, while DYNE-302 (FSHD) and DYNE-401 (Pompe) are in earlier preclinical development.
Show full overview
Z-rostudirsen carries Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA, plus Orphan Drug designation from the FDA, EMA, and Japanese Ministry of Health, Labour and Welfare — designations that support a priority review pathway but do not guarantee approval. The FDA placed z-rostudirsen on clinical hold in January 2022 before clearing the IND in July 2022 following additional information submissions, illustrating the regulatory binary risk inherent in the program. Confirmatory Phase 3 trials for z-rostudirsen and z-basivarsen are planned to initiate in Q2 2026 and March 2026, respectively; failure to verify clinical benefit in confirmatory trials could result in withdrawal of any Accelerated Approval granted.
See also: Healthcare · Biotechnology
From Dyne Therapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-15Recent Developments — Dyne Therapeutics, Inc.
Latest news
- NEWS Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basiv — benzinga Jun 3, 2026 positive
- NEWS Dyne Therapeutics Submits Biologics License Application To FDA For Zeleciment Rostudirsen To Duchenne Muscular Dystrophy — benzinga May 26, 2026 positive
- NEWS Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystr — benzinga May 20, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33 — benzinga May 15, 2026 positive
- NEWS Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24 — benzinga May 13, 2026 positive
Generated 2026-06-17T08:56:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinez-rostudirsen (DMD exon 51)10-K Item 1: 'We plan to submit a biologics license application, or BLA, to the U.S. Food and Drug Administration, or FDA, for U.S. Accelerated Approval of z-rostudirsen for DMD patients who have mutations amenable to exon 51 skipping in the second quarter of 2026'
- HIGHpipelinez-basivarsen (DM1)10-K Item 1: 'We plan to submit a BLA to the FDA for U.S. Accelerated Approval of z-basivarsen for DM1 patients early in the third quarter of 2027.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.72: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Elevated put/call ratio: 11.50; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Prior stop was $17.40. Score 5.2/10, moderate confidence.
Take-profit target: $34.43 (+84.0% upside). Prior stop was $17.40. Stop-loss: $17.40.
Concentration risk — Pipeline: z-rostudirsen (DMD exon 51); Concentration risk — Pipeline: z-basivarsen (DM1); Quality below floor (1.6 < 4.0).
Dyne Therapeutics, Inc. trades at a P/E of N/A (forward -6.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover DYN with a consensus score of 4.2/5. Average price target: $38.
What does Dyne Therapeutics, Inc. do?Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases,...
Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases, with lead assets z-rostudirsen (DYNE-251) for DMD exon 51 skipping and z-basivarsen (DYNE-101) for DM1. BLA submission for z-rostudirsen planned Q2 2026 for U.S. Accelerated Approval; Phase 3 confirmatory trials for both programs planned in 2026.